Is the P21 peptide the same as the p21 protein?

No — they are entirely unrelated and share only a name. p21^Cip1/Waf1 is a well-studied cell-cycle protein that halts cell division and features heavily in cancer and senescence research. The peptide sold as P21 is a small CNTF-derived compound studied for neurogenesis. A paper about p21 is almost certainly not about the peptide.

What is the P21 peptide derived from?

From the active region of ciliary neurotrophic factor, a protein involved in nerve cell survival and development. CNTF itself is large, difficult to deliver and cannot cross into the brain usefully, so researchers identified the small region responsible for the effect and built only that portion.

What is P21 studied for?

Neurogenesis — the formation of new neurons in the adult brain, principally in the hippocampus, which is central to memory. In mouse studies it has been reported to increase measures of neurogenesis and improve performance on learning tasks.

Are there human trials of the P21 peptide?

None have been published, including early-phase studies. The available research is preclinical mouse work, coming largely from the group that developed the compound. That is normal for this stage of development but means the findings have not been widely replicated by independent laboratories.

Why is the animal evidence not enough for cognition?

Because cognition has one of the widest and most consistently disappointing gaps between animal and human results of any research area. A mouse performing better on a maze task is a genuine finding and a very long way from human memory. The history of cognitive compounds is substantially a history of effects that were robust in rodents and did not appear in people.

Research Library›Bioregulators & Neuropeptides›P21 (Peptide)

Commonly Confused

P21 — The Peptide With Somebody Else's Name

Q: Why did you use the URL p21-peptide instead of p21?

To avoid contributing to the naming collision. Because the cell-cycle protein p21 appears throughout senescence and longevity research, its literature sits close enough to the anti-ageing conversation to be mistaken for relevant, and we would rather our own URL not add to that confusion.

Search for P21 and you will find thousands of papers about a cancer-related protein that has nothing to do with the compound sold under that name. Sorting that out is most of what a reader needs here.

7 min read·3 studies cited·Updated August 2026

Evidence level

Preclinical only — animal and cell studies

Mouse work only; no published human trials

What this level means

Quick Reference

The peptide	A small CNTF-derived neurogenic compound
Derived from	Ciliary neurotrophic factor (CNTF)
The OTHER p21	p21^Cip1/Waf1 — a cell-cycle protein, unrelated
Studied for	Neurogenesis and cognition, in mice
Human trials	None published

Two Completely Different Things, One Name

Before anything else about this compound, the naming problem — because it will otherwise waste your time and can actively mislead you.

"p21" is a long-established name in cell biology for p21^Cip1/Waf1, a protein that halts cell division. It is central to how cells stop replicating when damaged, it is heavily studied in cancer and in cellular senescence, and it has thousands of papers behind it. It is a genuinely important molecule.

It has nothing whatever to do with the peptide sold as P21. Different molecule, different origin, different field, different everything. They share a label and no more.

It is two unrelated people with the same common name. Search the name and you get the famous one — and if you are not paying attention, you can come away thinking you have read about the other. That is not a hypothetical: because the cell-cycle protein appears in senescence and longevity research, its literature sits close enough to the anti-ageing conversation to be mistaken for relevant.

So the practical rule: a paper about p21 is almost certainly not about this peptide. Anyone citing the volume of p21 research as evidence for the peptide is either confused or relying on you being so. We have deliberately given this page the URL p21-peptide rather than p21 for the same reason.

What the Peptide Actually Is

The compound sold as P21 is a small peptide derived from the active region of ciliary neurotrophic factor, or CNTF — a protein involved in the survival and development of nerve cells. It was developed by researchers at the New York State Institute for Basic Research in Developmental Disabilities.

The reasoning behind it is a recurring one in this library. CNTF itself is a large protein: hard to make, hard to deliver, and unable to cross into the brain in any useful quantity. So rather than attempting to deliver the whole thing, the researchers identified the small region responsible for the effect they wanted and built just that.

It is quoting a sentence instead of posting the book. If one paragraph carries the instruction, the remaining three hundred pages are weight, cost and delivery difficulty. A short peptide can go places a large protein cannot — which is the same logic that produced GRF(1-29) from GHRH in CJC-1295 and TB-500 from Thymosin Beta-4.

The stated interest is neurogenesis — the formation of new neurons in the adult brain, principally in the hippocampus, a region central to memory. In mouse studies the peptide has been reported to increase measures of neurogenesis and to improve performance on learning tasks.

How Far the Evidence Actually Goes

This section is short, because the honest answer is short.

The published work is preclinical. It is mice. There are no published human trials of this peptide — not small ones, not early-phase ones. The research comes largely from the group that developed it, which is normal for a compound at this stage and does mean the findings have not been widely replicated by independent laboratories.

That places it at the earliest stage described in how to read peptide research, and cognition is a particularly unforgiving area for that stage. A mouse performing better in a water maze is a real finding and a very long way from anything about human memory. The history of cognitive compounds is substantially a history of results that were robust in rodents and vanished in people — this is one of the fields where the animal-to-human gap has been widest and most consistently disappointing.

None of that makes the compound uninteresting. The design reasoning is sound and the target is legitimate. It does mean that anything written about what P21 does for human cognition is extrapolation, and should be read as such regardless of how confidently it is phrased.

P21 is covered here mainly because the naming collision is a genuine trap, and because anyone meeting the compound alongside better-evidenced nootropic peptides deserves to know how far apart they are. For those, see Semax vs Selank.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated August 2026.

Browse the research range →

Published References

Chohan MO, Li B, Blanchard J, et al. “Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide.” Neurobiology of aging, 2011. PubMed
Bolognin S, Buffelli M, Puoliväli J, et al. “Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.” Neurobiology of aging, 2014. PubMed
Abbas T, Dutta A. “p21 in cancer: intricate networks and multiple activities.” Nature reviews. Cancer, 2009. PubMed